Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.42
-5.45 (-3.87%)
Official Closing Price
Updated: 4:10 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
54
55
Next >
These 3 Companies Can Be the Next Stock-Split Stocks in 2024
December 29, 2023
Since mid-2021, Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk have conducted stock splits. Three well-known companies look set to follow in...
Via
The Motley Fool
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
December 27, 2023
Via
Benzinga
Meet the Stock-Split Stock Warren Buffett Is Likeliest to Buy in 2024
December 27, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a stock-split stock that checks all the right boxes for the Oracle of Omaha.
Via
The Motley Fool
(NVO) - Analyzing Novo Nordisk's Short Interest
December 25, 2023
Via
Benzinga
3 Stock-Split Stocks Billionaires Are Piling Into Ahead of 2024
December 25, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three industry leaders Wall Street's brightest money managers want to own for...
Via
The Motley Fool
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
December 21, 2023
Via
Benzinga
Novo Nordisk, Maker Of 'Miracle' Weight Loss Drug Ozempic, Announces Mega Factory In Dublin
December 24, 2023
Via
Benzinga
Will Novo Nordisk Be Worth More Than Meta Platforms by 2030?
December 23, 2023
The gap in market cap between these two companies is big today, but it could shrink in the future.
Via
The Motley Fool
Fake Ozempic - FDA and Novo Nordisk Warn Against Counterfeit Ozempic Penetrating US Market Amid High Demand
December 22, 2023
The FDA on Thursday said it continues to investigate counterfeit Novo Nordisk A/S's&n
Via
Benzinga
Exposures
Product Safety
7 Low-Volatility Stocks for Stable Growth in 2024
December 21, 2023
Wager on these stocks to buy for stable growth, handpicked for their low volatility and potential to weather economic headwinds.
Via
InvestorPlace
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
December 21, 2023
Which weight-loss stocks are good buys today?
Via
The Motley Fool
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.
December 21, 2023
Diabetes and weight-loss drugs won't be the hottest category of medicines forever.
Via
The Motley Fool
Why Novo Nordisk Stock Was Up on a Down Day for the Market
December 20, 2023
As if the company's top two products weren't popular enough, a new media report made them even more appealing.
Via
The Motley Fool
Weight Loss Drugs By Novo Nordisk, Eli Lilly Don't Deter Nestle's Coffee Demand - CEO Explains Why
December 20, 2023
Nestle S.A. (OTC: NSRGY) CEO Mark Schneider stated that despite the rising use of weight loss medications like Eli Lilly And Company's (NYSE: LLY) Zepbound and Novo Nordisk's
Via
Benzinga
These 2 Unstoppable Stocks Could Make You Richer in 2024 and Beyond
December 20, 2023
Eli Lilly and Novo Nordisk are disrupting the weight-loss market with treatments like Mounjaro and Ozempic.
Via
The Motley Fool
Novo Nordisk Collaborates With India's Online Marketplace To Remove Unauthorized Wegovy Listings
December 19, 2023
IndiaMART, an online marketplace in India, has reportedly taken action to remove unauthorized listings of Novo Nordisk A/S's (NYSE: NVO) highly sought-after weight-loss drug Wegovy after engaging in...
Via
Benzinga
LifeMD expands telehealth GLP-1weight-loss service with Medifast
December 19, 2023
LifeMD Inc. (NASDAQ: LFMD) is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing
Via
MarketBeat
3 Stocks With the Potential to Be 2024’s Company of the Year
December 18, 2023
Finding the top stocks for 2024 is like looking for a needle in a haystack. Nonetheless, some of these names could be company of the year.
Via
InvestorPlace
Obesity/Diabetes Drug Class GLP-1s' Cost-Saving Potential: Decoding Impact on Healthcare Spending
December 18, 2023
Due to the recent achievements of GLP-1s, Goldman Sachs sees significant potential for Eli Lilly And Co (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), and other companies to venture
Via
Benzinga
Wegovy's Success Spurs Novo Nordisk Foundation's Philanthropic Initiative To Enhance Respiratory Disease Vaccines
December 18, 2023
The Novo Nordisk Foundation pledged 1.8 billion Danish crowns ($265 million) toward an initiative to enhance vaccines for respiratory illnesses.
Via
Benzinga
Why Novo Nordisk Stock Is Moving Higher Today
December 18, 2023
An Indian e-commerce company is helping Novo Nordisk combat illegal sales of weight loss drug Wegovy.
Via
The Motley Fool
Topics
Law Enforcement
Exposures
Legal
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
December 18, 2023
2024 is going to be a sizzler in the biopharma sector.
Via
The Motley Fool
As 2023 Comes To A Close And Updates Are Expected From Many Companies, Are These Three Unique Biotech Names On Your Watchlist?
December 18, 2023
Biotech stocks have had a tough run in 2023 so far. As of early November, the iShares Biotechnology ETF (IBB) was down 7.5% while the S&P 500 was up more than 14%.
Via
Benzinga
Topics
ETFs
25% of Warren Buffett's Secret Portfolio Is Invested in These 3 ETFs. Here's Why They're Great Picks for 2024.
December 18, 2023
Buffett didn't personally pick these ETFs. But all three could make him money in the new year.
Via
The Motley Fool
Topics
ETFs
3 Stock-Split Stocks With 51% to 128% Upside in 2024, According to Select Wall Street Analysts
December 18, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three high-flying stocks a trio of Wall Street analysts believe can soar in the...
Via
The Motley Fool
If You Had Invested $10,000 in Novo Nordisk in 2018, This Is How Much You Would Have Today
December 17, 2023
Is it too late to invest in this fast-growing pharmaceutical company?
Via
The Motley Fool
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.
December 16, 2023
Lilly's weight loss drug appears to be on the way to becoming a megablockbuster.
Via
The Motley Fool
Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO
December 15, 2023
Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering.
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
The New Magnificent 7: 7 Stocks Rising to Prominence
December 15, 2023
The next magnificent 7 stocks continue to rise to prominence and offer strong returns to investors and are generally stable.
Via
InvestorPlace
Ozempic Isn't the Best Weight-Loss Treatment Anymore. Here's Why That Shouldn't Matter to Novo Nordisk Investors.
December 14, 2023
Investors shouldn't be quick to discount Novo Nordisk's long-term potential.
Via
The Motley Fool
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.